A Study to Assess the Safety and Efficacy of Oral LPCN 1154A in Women With Severe PPD
Trial details
- Registry ID
- NCT06979544
- Drugs studied
- LPCN 1154A
TrialRedline tracks 4 clinical trials sponsored by Lipocine Inc.: 1 Phase 3, 3 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Study to Assess the Safety and Efficacy of Oral LPCN 1154A in Women With Severe PPDNCT06979544 | LPCN 1154A | Completed | 2026-01-16Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Study to Assess the Efficacy, Safety, and Tolerability of Oral LPCN 1148 in Male Subjects With Cirrhosis of the Liver and SarcopeniaNCT04874350 | LPCN 1148 | Completed | 2023-12-18Actual |
| A Study of the Safety and Tolerability of LPCN 1144 in Subjects Who Completed the LPCN 1144-18-002 TrialNCT04685993 | LPCN 1144 | Completed | 2022-03-01Actual |
| The Efficacy, Safety and Tolerability of Oral LPCN 1144 in Subjects With Nonalcoholic SteatohepatitisNCT04134091 | LPCN 1144 Formulation A, LPCN 1144 Formulation B | Completed | 2021-06-24Actual |
Names as written in the registry records.
NCT06979544 · Lipocine Inc.
Before: Estimated. After: Actual.
Before: 80 participants (planned). After: 90 participants (actual).
Before: Estimated. After: Actual.
Before: Apr 2026. After: 16 Jan 2026.
Before: Recruiting. After: Completed.